NOIDA, India--28 Jun--PRNewswire-AsiaNet/InfoQuest
Jubilant Discovery Services Inc., Bedminster, New Jersey, a Jubilant Life Sciences Company, announced today that it has entered into a drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium, that will aim to deliver preclinical candidates to Janssen. The alliance is set to span an initial period of 3 years and will focus on multiple targets in the area of neuroscience.
Under the terms of the alliance agreement, Janssen will transfer ongoing efforts on selected drug discovery targets to Jubilant. Jubilant shall then carry out the research services and deliver preclinical candidates to Janssen for possible further development and commercialization. In addition to receiving research funding, Jubilant may also be eligible to receive milestones and royalties should Janssen successfully develop and commercialize the candidates.
Commenting on this development, Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant, said: "We are very pleased to collaborate with Janssen, a world leader in pharmaceutical research and commercialization. The collaboration will utilize Jubilant's global research network to include our new research facility in the US focused in the area of neuroscience, in addition to our India-based research centers. We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry."
About Jubilant
Jubilant Discovery Services is New Jersey based US subsidiary of Jubilant Biosys Ltd, a Jubilant Life Sciences Company. It will focus on providing Target Validation and Screening solutions to its global collaborators and more significantly in real time for the US based collaborators. The facility will integrate its activities with R&D facilities of Jubilant in India as well as of its US collaborators to support Lead Generation and Target validation efforts. Staffed with personnel with screening expertise, it will focus in areas of Ion channels, EPHys and screening platforms in GPCR's and Kinases.
Jubilant Life Sciences Limited is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution (DDDS) provider out of India. The Company provides Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities and a team of ~ 5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 70 countries. The Company is well recognized as a 'Partner of Choice' by leading life sciences companies worldwide.
For more info: http://www.jubl.com
Contact for Business Queries
+919611104886
SOURCE: Jubilant Discovery Services Inc.
AsiaNet 45270
-- Distributed by AsiaNet ( www.asianetnews.net ) --
บริษัทจะมอบวัคซีนแบบฉีดครั้งเดียวจำนวนสูงสุด 400 ล้านโดสให้ประเทศสมาชิกสหภาพแอฟริกา วัคซีนดังกล่าวจะมอบให้ได้ก็ต่อเมื่อได้รับการอนุมัติจากฝ่ายกำกับดูแลของแต่ละประเทศ ข้อมูลแสดงให้เห็นว่า วัคซีนทดลองที่บริษัทเป็นผู้พัฒนาช่วยป้องกันไม่ให้ผู้ป่วยโควิด-19 ต้องเข้าโรงพยาบาลและเสียชีวิตครอบคลุมหลากหลายพื้นที่ทางภูมิศาสตร์ ซึ่งรวมถึงผู้ติดเชื้อไวรัสกลายพันธุ์ในสายพันธุ์ที่กำลังน่าเป็นห่วง Janssen Pharmaceutica NV ในเครือ Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (บริษัท)